Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) rose 7.9% on Thursday . The company traded as high as $69.36 and last traded at $68.29, with a volume of 665,216 shares traded. The stock had previously closed at $63.28.

A number of brokerages have weighed in on RARE. JPMorgan Chase & Co. set a $110.00 target price on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Monday, August 8th. Credit Suisse Group AG restated a “buy” rating and issued a $101.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 25th. Canaccord Genuity restated a “buy” rating and issued a $120.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 15th. Jefferies Group restated a “buy” rating and issued a $109.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, May 10th. Finally, Cowen and Company restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $100.41.

The company has a 50-day moving average of $56.49 and a 200-day moving average of $61.48. The stock’s market cap is $2.59 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.02. During the same quarter in the prior year, the firm posted ($0.83) EPS. Equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post ($5.89) earnings per share for the current year.

In related news, insider Sunil Agarwal sold 650 shares of the business’s stock in a transaction dated Monday, June 20th. The shares were sold at an average price of $54.16, for a total transaction of $35,204.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $59.95, for a total transaction of $1,199,000.00. Following the transaction, the chief executive officer now owns 526,704 shares in the company, valued at approximately $31,575,904.80. The disclosure for this sale can be found here.

Several institutional investors recently made changes to their positions in the stock. California Public Employees Retirement System boosted its position in shares of Ultragenyx Pharmaceutical by 7.6% in the fourth quarter. California Public Employees Retirement System now owns 55,300 shares of the biopharmaceutical company’s stock valued at $6,204,000 after buying an additional 3,900 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock valued at $6,414,000 after buying an additional 5,139 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at about $1,010,000. Jennison Associates LLC boosted its position in shares of Ultragenyx Pharmaceutical by 17.0% in the fourth quarter. Jennison Associates LLC now owns 755,388 shares of the biopharmaceutical company’s stock valued at $84,739,000 after buying an additional 109,724 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 2,393,587 shares of the biopharmaceutical company’s stock valued at $268,512,000 after buying an additional 275,497 shares in the last quarter.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.